Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Merck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...

Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the primary endpoint in a Phase 3 trial for a certain type of ovarian cancer.

Keytruda plus chemo showed ... an overall survival benefit in ovarian cancer,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 therapy Keytruda (pembrolizumab) in ovarian cancer. The phase 3 KEYNOTE-B96 ...

RAHWAY, N.J. – Merck & Co., Inc., a global healthcare ... particularly in treating challenging forms of ovarian cancer. Currently, KEYTRUDA is not approved for the treatment of ovarian cancer ...

“This marks the first time a Keytruda-based ... overall survival benefit in ovarian cancer,” said Dr Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.

Currently, KEYTRUDA is not approved for the treatment of ovarian cancer, but it has multiple approved indications in the United States for other cancers, including melanoma, non-small cell lung cancer ...